文献速递心律失常血脂与心血管预防

非瓣膜性房颤口服抗凝持续性的预测因素、时间趋势与结局:荷兰全国队列研究

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.
PubMed 文献 · Eur Heart J · 2021-01-01

该荷兰全国队列纳入2013–2018年起始DOAC的非瓣膜性房颤患者93 048例,以末次处方至研究结束间隔100天定义非持续性。4年内至少四分之一患者非持续,非持续与缺血性卒中及卒中相关死亡复合结局风险升高相关。

要点

  • 4年时口服抗凝持续率为72.0%,提示至少四分之一患者非持续。
  • 非持续与缺血性卒中/卒中相关死亡复合结局风险升高相关(aHR 1.79)。
  • 女性、65–74岁、永久性房颤、既往VKA暴露、卒中史及CHA2DS2-VASc≥2与更好持续性相关。

核心结论

  • 至少四分之一非瓣膜性房颤患者在4年内非持续口服抗凝,且与缺血性卒中预防效果不佳相关。
  • 识别的基线特征可能有助于识别非持续风险患者。

研究设计与样本

  • 荷兰全国统计纳入2013–2018年起始DOAC用于缺血性卒中预防的DOAC初治非瓣膜性房颤患者。
  • 共纳入93 048例患者,以末次处方至研究结束间隔100天定义口服抗凝非持续。

主要发现

  • 口服抗凝持续累积发生率在1、2、3、4年分别为88.1%(95%CI 87.9–88.3%)、82.6%(95%CI 82.3–82.9%)、77.7%(95%CI 77.3–78.1%)、72.0%(95%CI 71.5–72.5%)。
  • 与持续口服抗凝相比,非持续与缺血性卒中及缺血性卒中相关死亡复合结局风险升高相关(aHR 1.79,95%CI 1.49–2.15)。
  • 非持续与缺血性卒中风险升高相关(aHR 1.58,95%CI 1.29–1.93)。
  • 与更好口服抗凝持续性相关的基线特征包括女性、65–74岁、永久性房颤、既往维生素K拮抗剂暴露、卒中史(包括短暂性脑缺血发作)及CHA2DS2-VASc评分≥2。
  • 75.7%患者基线CHA2DS2-VASc评分≥2。

临床怎么用

  • 对非瓣膜性房颤DOAC治疗患者应关注口服抗凝持续性,尤其具有非持续风险特征者。
  • 非持续与缺血性卒中预防效果不佳相关,提示需加强随访和依从性管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied. We investigated the persistence with oral anticoagulants (OACs) and its association with prognosis among a nationwide cohort of NVAF patients. METHODS AND RESULTS: DOAC-naive NVAF patients who started to use DOACs for ischaemic stroke prevention between 2013 and 2018 were included using Dutch national statistics. Persistence with OACs was determined based on the presence of a 100-day gap between the last prescription and the end of study period. In 93 048 patients, 75.7% had a baseline CHA2DS2-VASc score of ≥2. The cumulative incidence of persistence with OACs was 88.1% [95% confidence interval (CI) 87.9-88.3%], 82.6% (95% CI 82.3-82.9%), 77.7% (95% CI 77.3-78.1%), and 72.0% (95% CI 71.5-72.5%) at 1, 2, 3, and 4 years after receiving DOACs, respectively. Baseline characteristics associated with better persistence with OACs included female sex, age range 65-74 years, permanent atrial fibrillation, previous exposure to vitamin K antagonists, stroke history (including transient ischaemic attack), and a CHA2DS2-VASc score ≥2. Non-persistence with OACs was associated with an increased risk of the composite outcome of ischaemic stroke and ischaemic stroke-related death [adjusted hazard ratio (aHR) 1.79, 95% CI 1.49-2.15] and ischaemic stroke (aHR 1.58, 95% CI 1.29-1.93) compared with being persistent with OACs. CONCLUSION: At least a quarter of NVAF patients were non-persistent with OACs within 4 years, which was associated with poor efficacy of ischaemic stroke prevention. The identified baseline characteristics may help identify patients at risk of non-persistence.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Toorop MMA, Chen Q, Tichelaar VYIG, et al. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study. Eur Heart J. 2021. PMID: 34269375. doi:10.1093/eurheartj/ehab421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。